Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4

Fischer, Alyssa; Rosen, Alyx C.; Ensslin, Courtney J.; Wu, Shenhong; Lacouture, Mario E.

doi:10.1111/dth.12027

Cited by 44 publications

(32 citation statements)

References 94 publications

(143 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This possible mechanism could be similar to pruritus in patients receiving ipilimumab therapy for metastatic melanoma. Pruritus in patients undergoing treatment with ipilimumab is believed to be a result of the enhanced immunologic response in the skin, therefore releasing cytokines and chemokines .…”

Section: Discussionmentioning

confidence: 99%

Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant

et al. 2013

View full text Add to dashboard Cite

Pruritus is a symptom that significantly affects the patient's quality of life in cutaneous T cell lymphoma (CTCL). The most effective treatments are those that address the condition itself; however, it is often not possible to control this symptom. Lymphoma-related pruritus normally becomes more severe as CTCL progresses, constituting an important factor for quality of life in these patients. Substance P is a neuromodulator which appears to play a key role in pruritus. Aprepitant is a neurokinin-1 receptor antagonist affecting the substance P receptor. So far, several cases have been documented with an antipruritic response to the drug aprepitant in advanced-stage mycosis fungoides (MF). In this paper, we describe an excellent response to aprepitant in a female patient with severe pruritus secondary to hypopigmented stage I MF. We would also like to stress the absence of nausea and vomiting of this combined therapy of interferon and aprepitant. Aprepitant could improve tolerance to interferon.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Pruritus often occurs concomitantly with xerosis following EGFRi administration with the highest incidence rate seen in cetuximab followed by erlotinib (Fischer et al, 2013). Paronychia occurs after 2 to 3 months of therapy.…”

Section: Pathophysiology and Clinical Presentationmentioning

confidence: 99%

“…Oral therapy for pruritus can include antihistamines such as diphenhydramine, hydroxyzine, and cetirizine (Lacouture et al, 2011). For refractory pruritus, GABA agonists oral antidepressants (Fischer et al, 2013) and aprepitant have been used in clinic practice.…”

Section: Pruritusmentioning

confidence: 99%

Dermatologic Reactions to Targeted Therapy

Barton-Burke

Ciccolini

Mekas

et al. 2017

Nursing Clinics of North America

View full text Add to dashboard Cite

Synopsis Cancer treatments usually have side effects of bone marrow depression, mucositis, hair loss, and gastrointestinal issues. Rarely do we think of skin side effects until patients have been treated successfully with EGFRi as they commonly experienced skin reactions. Those skin reactions include papulopustular rash, hair changes, radiation dermatitis enhancement, pruritus, mucositis, xerosis, fissures, and paronychia. This paper discusses the common skin reactions seen when using EGFRi. This paper presents an overview of skin as the largest and important organ of the body including an overview of skin assessment, pathophysiology of the skin reactions, nursing care involved and introduction to the emerging cancer nursing specialty of oncodermatology.

show abstract

“…Pruritus associated with ipilimumab use is the direct result of CTLA-4 inhibition, resulting in activation of the immune system, specifically amplified T cell recognition of self-antigens (29). Histological analyses of the rashes have shown a perivascular lymphocytic and sometimes eosinophilic infiltrate that extends into the epidermis (24, 25).…”

Section: Iraes In Various Organ Systemsmentioning

confidence: 99%

Immune-mediated adverse events of anticytotoxic T lymphocyte–associated antigen 4 antibody therapy in metastatic melanoma

Quirk

Shure

Agrawal

2015

Translational Research

View full text Add to dashboard Cite

Ipilimumab, an antibody that blocks cytotoxic T lymphocyte-associated antigen-4 (CTLA-4; CD152), was approved by the Food and Drug Administration (FDA) in 2011 for the treatment of unresectable stage III or IV malignant melanoma. Although the addition of this particular immunotherapy has broadened treatment options, immune-related adverse events (irAEs) are associated with ipilimumab therapy, including dermatologic effects, colitis and diarrhea, endocrine effects, hepatotoxicity, ocular effects, renal effects, neurologic effects, and others. In this article, a critical evaluation of the underlying mechanisms of irAEs associated with anti-CTLA-4 therapy is presented. Additionally, potentially beneficial effects of combinational therapies to alleviate ipilimumab-induced irAEs in malignant melanoma are discussed. Future research is warranted to elucidate the efficacy of such combination therapies as well as specific biomarkers that would help to predict a clinical response to ipilimumab in patients with malignant melanoma.

show abstract

Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4

Cited by 44 publications

References 94 publications

Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant

Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant

Dermatologic Reactions to Targeted Therapy

Immune-mediated adverse events of anticytotoxic T lymphocyte–associated antigen 4 antibody therapy in metastatic melanoma

Contact Info

Product

Resources

About